← Search & browse all drugs
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Hydroxyquinoline derivatives
broxyquinoline
P01AA01
Forms & Strengths
- Oral tablets: 200 mg to 500 mg (varies by regional manufacturer)
Adult Dosing
- Amebiasis: 200 mg to 500 mg orally three times daily for 7 to 10 days
- Infectious diarrhea: 200 mg to 500 mg orally three times daily for 5 to 7 days
Pediatric Dosing
- Children > 6 years: 200 mg orally two to three times daily
- Children < 6 years: Safety and efficacy not well established; use generally avoided
Indications
- Intestinal amebiasis caused by Entamoeba histolytica
- Acute and chronic infectious diarrhea
- Traveller's diarrhea
Mechanism of Action
- Halogenated 8-hydroxyquinoline derivative with luminal amebicidal and antibacterial activity
- Chelates trace metals essential for pathogen survival and inhibits protozoal and bacterial enzymes
Contraindications
- Hypersensitivity to broxyquinoline, hydroxyquinolines, or iodine-containing compounds
- Severe hepatic impairment
- Severe renal impairment
- Pre-existing optic neuropathy or severe neurological disorders
Adverse Reactions
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea (transient)
- Allergic skin reactions (rash, pruritus)
- Peripheral neuropathy (with prolonged or high-dose use)
- Optic neuritis (rare, associated with chronic quinoline toxicity)
Drug Interactions
- Halogenated hydroxyquinolines may interfere with thyroid function tests due to iodine content
- Concurrent use with other neurotoxic agents may increase the risk of peripheral neuropathy
- Antacids containing aluminum, calcium, or magnesium may decrease absorption
Curated Content: Needs Vetting Before Put to Clinical Use